Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1993 Apr 17;306(6884):1030–1034. doi: 10.1136/bmj.306.6884.1030

Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography.

I Jacobs 1, A P Davies 1, J Bridges 1, I Stabile 1, T Fay 1, A Lower 1, J G Grudzinskas 1, D Oram 1
PMCID: PMC1677033  PMID: 8490497

Abstract

OBJECTIVE--To assess the performance of the sequential combination of serum CA 125 measurement and ultrasonography in screening for ovarian cancer. DESIGN--The serum CA 125 concentration of each subject was determined and those with a concentration > or = 30 U/ml were recalled for abdominal ultrasonography. If ultrasonography gave abnormal results surgical investigation was arranged. Volunteers were followed up by annual postal questionnaire. SETTING--General practice, occupational health departments, ovarian cancer screening clinic. SUBJECTS--22,000 women volunteers who were postmenopausal and aged over 45 years. MAIN OUTCOME MEASURES--Apparent sensitivity, specificity, positive predictive value, years of cancer detected. RESULTS--41 women had a positive screening result and were investigated surgically. 11 had ovarian cancer (true positive result) and 30 had other disorders or no abnormality (false positive result). Of the 21,959 volunteers with a negative screening result, eight subsequently presented clinically with ovarian cancer (false negative result) and 21,951 had not developed ovarian cancer during follow up (apparent true negative result). The screening protocol achieved a specificity of 99.9%, a positive predictive value of 26.8%, and an apparent sensitivity of 78.6% and 57.9% at one year and two year follow up respectively. The estimated number of years of cancer detected by the prevalence screen was 1.4 years. CONCLUSIONS--This screening protocol is highly specific for ovarian cancer and can detect a substantial proportion of cases at a preclinical stage. Further investigation is required to determine the effect of the screening protocol on the ratio of early to late stage disease detected and on mortality from ovarian cancer.

Full text

PDF
1030

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Annegers J. F., Strom H., Decker D. G., Dockerty M. B., O'Fallon W. M. Ovarian cancer: incidence and case-control study. Cancer. 1979 Feb;43(2):723–729. doi: 10.1002/1097-0142(197902)43:2<723::aid-cncr2820430248>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  2. Bast R. C., Jr, Feeney M., Lazarus H., Nadler L. M., Colvin R. B., Knapp R. C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov;68(5):1331–1337. doi: 10.1172/JCI110380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bast R. C., Jr, Knauf S., Epenetos A., Dhokia B., Daly L., Tanner M., Soper J., Creasman W., Gall S., Knapp R. C. Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer. 1991 Oct 15;68(8):1758–1763. doi: 10.1002/1097-0142(19911015)68:8<1758::aid-cncr2820680819>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  4. Bourne T., Campbell S., Steer C., Whitehead M. I., Collins W. P. Transvaginal colour flow imaging: a possible new screening technique for ovarian cancer. BMJ. 1989 Dec 2;299(6712):1367–1370. doi: 10.1136/bmj.299.6712.1367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Campbell S., Bhan V., Royston P., Whitehead M. I., Collins W. P. Transabdominal ultrasound screening for early ovarian cancer. BMJ. 1989 Dec 2;299(6712):1363–1367. doi: 10.1136/bmj.299.6712.1363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Campbell S., Goessens L., Goswamy R., Whitehead M. Real-time ultrasonography for determination of ovarian morphology and volume. A possible early screening test for ovarian cancer? Lancet. 1982 Feb 20;1(8269):425–426. doi: 10.1016/s0140-6736(82)91622-1. [DOI] [PubMed] [Google Scholar]
  7. Cole L. A., Nam J. H., Chambers J. T., Schwartz P. E. Urinary gonadotropin fragment, a new tumor marker. II. Differentiating a benign from a malignant pelvic mass. Gynecol Oncol. 1990 Mar;36(3):391–394. doi: 10.1016/0090-8258(90)90149-f. [DOI] [PubMed] [Google Scholar]
  8. Einhorn N., Sjövall K., Knapp R. C., Hall P., Scully R. E., Bast R. C., Jr, Zurawski V. R., Jr Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 1992 Jul;80(1):14–18. [PubMed] [Google Scholar]
  9. Hildreth N. G., Kelsey J. L., LiVolsi V. A., Fischer D. B., Holford T. R., Mostow E. D., Schwartz P. E., White C. An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol. 1981 Sep;114(3):398–405. doi: 10.1093/oxfordjournals.aje.a113207. [DOI] [PubMed] [Google Scholar]
  10. Jacobs I. J., Oram D. H., Bast R. C., Jr Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3. Obstet Gynecol. 1992 Sep;80(3 Pt 1):396–399. [PubMed] [Google Scholar]
  11. Jacobs I., Bast R. C., Jr The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989 Jan;4(1):1–12. doi: 10.1093/oxfordjournals.humrep.a136832. [DOI] [PubMed] [Google Scholar]
  12. Jacobs I., Stabile I., Bridges J., Kemsley P., Reynolds C., Grudzinskas J., Oram D. Multimodal approach to screening for ovarian cancer. Lancet. 1988 Feb 6;1(8580):268–271. doi: 10.1016/s0140-6736(88)90351-0. [DOI] [PubMed] [Google Scholar]
  13. Narod S. A., Feunteun J., Lynch H. T., Watson P., Conway T., Lynch J., Lenoir G. M. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet. 1991 Jul 13;338(8759):82–83. doi: 10.1016/0140-6736(91)90076-2. [DOI] [PubMed] [Google Scholar]
  14. Schwartz P. E., Chambers S. K., Chambers J. T., Gutmann J., Katopodis N., Foemmel R. Circulating tumor markers in the monitoring of gynecologic malignancies. Cancer. 1987 Aug 1;60(3):353–361. doi: 10.1002/1097-0142(19870801)60:3<353::aid-cncr2820600312>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  15. Ward B. G., Cruickshank D. J., Tucker D. F., Love S. Independent expression in serum of three tumour-associated antigens: CA 125, placental alkaline phosphatase and HMFG2 in ovarian carcinoma. Br J Obstet Gynaecol. 1987 Jul;94(7):696–698. doi: 10.1111/j.1471-0528.1987.tb03178.x. [DOI] [PubMed] [Google Scholar]
  16. Zurawski V. R., Jr, Orjaseter H., Andersen A., Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer. 1988 Nov 15;42(5):677–680. doi: 10.1002/ijc.2910420507. [DOI] [PubMed] [Google Scholar]
  17. Zurawski V. R., Jr, Sjovall K., Schoenfeld D. A., Broderick S. F., Hall P., Bast R. C., Jr, Eklund G., Mattsson B., Connor R. J., Prorok P. C. Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol. 1990 Mar;36(3):299–305. doi: 10.1016/0090-8258(90)90130-d. [DOI] [PubMed] [Google Scholar]
  18. van Nagell J. R., Jr, Higgins R. V., Donaldson E. S., Gallion H. H., Powell D. E., Pavlik E. J., Woods C. H., Thompson E. A. Transvaginal sonography as a screening method for ovarian cancer. A report of the first 1000 cases screened. Cancer. 1990 Feb 1;65(3):573–577. doi: 10.1002/1097-0142(19900201)65:3<573::aid-cncr2820650331>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES